<DOC>
	<DOCNO>NCT02067416</DOCNO>
	<brief_summary>Study assay , Mammostrat® . verify utility predictor outcome tool determine would benefit chemotherapy prior surgery . Also could use clinical marker identify patient breast cancer benefit preoperative chemotherapy .</brief_summary>
	<brief_title>PREDATOR : Neoadjuvant Gene Prediction Breast Cancer</brief_title>
	<detailed_description>The purpose phase II study find test , Mammostrat® use predictor outcome tool determine best benefit chemotherapy prior surgery . This used determine Mammostrat assay may use clinical marker identify subset woman breast cancer benefit preoperative chemotherapy , either taxane/taxane-like ( T ) chemo agent anthracycline-based chemotherapy cyclophosphamide ( AC ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Patients histologic confirmation invasive breast carcinoma . 2 . Patients must intact primary tumor . 3 . ≥18 year age . 4 . Patients bilateral breast cancer eligible . 5 . Patients second primary breast cancer eligible . 6 . The primary breast tumor must ≥ 2 cm physical exam imaging . 7 . The tumor must determine HER2negative follow : Fluorescent situ hybridization ( FISH ) negative ( define ratio HER2 CEP17 must &lt; 2.2 ) Immunohistochemistry ( IHC ) 01+ ; IHC 2+ FISHnegative 8 . ECOG PS 0 , 1 , 2 . 9 . Negative serum pregnancy test ≤7 day treatment initiation serum urine pregnancy test must repeat ≤ 3 day prior start treatment woman childbearing potential ( WOCBP ) . For WOCBP , adequate contraception must use throughout study . For study , acceptable method contraception include reliable intrauterine device spermicide combination barrier method . Women already hormonal form birth control may continue treatment must also use barrier method . 10 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment . 11 . Patient must willing undergo breast biopsy require study protocol . 12 . Sufficient tissue must available diagnostic core biopsy . If , patient must undergo additional biopsy perform Mammostrat . 1 . Patients history invasive malignancy diagnose treat within previous 5 year , except nonmelanoma skin cancer noninvasive cervical cancer . 2 . Prior treatment investigational drug within precede 4 week . 3 . Evidence New York Heart Association class III great cardiac disease . 4 . History myocardial infarction , stroke , ventricular arrhythmia , symptomatic conduction abnormality within 6 month . 5 . Concurrent severe uncontrolled medical disease ( i.e. , active systemic infection , diabetes , hypertension , coronary artery disease , congestive heart Failure major surgery ) , opinion Investigator , would compromise safety patient compromise ability patient complete study . 6 . Pregnant nursing woman . 7 . Known allergic reaction Cremophor chemo agent trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neoadjuvant</keyword>
	<keyword>mammostrat</keyword>
	<keyword>TLE3</keyword>
	<keyword>DDR</keyword>
	<keyword>breast cancer</keyword>
</DOC>